Cargando…
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
OBJECTIVE: Long-acting β(2)-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) in COPD patients. Since the risk of combining a LABA with a LAMA could be greater, we have carried out a quantitativ...
Autores principales: | Rogliani, Paola, Matera, Maria Gabriella, Ora, Josuel, Cazzola, Mario, Calzetta, Luigino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723113/ https://www.ncbi.nlm.nih.gov/pubmed/29255354 http://dx.doi.org/10.2147/COPD.S146338 |
Ejemplares similares
-
Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019) -
Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022) -
LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017) -
Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences
por: Cazzola, Mario, et al.
Publicado: (2023) -
Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis
por: Rogliani, Paola, et al.
Publicado: (2019)